Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nexium label revision

This article was originally published in The Tan Sheet

Executive Summary

AstraZeneca revises the label for Nexium (esomeprazole) to update adverse events found in postmarketing use of the proton pump inhibitor. Possible side effects include "rare" cases of myalgia and hepatitis "with or without jaundice," the new label reads. AstraZeneca collected the adverse events through spontaneous reporting. Other PPI products such as TAP's Prevacid, Wyeth's Protonix and Proctor & Gamble's Prilosec OTC carry similar warnings. AstraZeneca is making the label change as promotions are underway for Nexium's use in combination with non-steroidal anti-inflammatory drugs (1"The Tan Sheet" May 9, 2005, p. 14)...

You may also be interested in...

Nexium Branded Campaign Highlights Use With NSAIDs

A campaign to promote the use of AstraZeneca's Nexium (esomeprazole) with NSAIDs broke with new TV spots April 29 and May 4

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts